Skip to main content
Clinical Trials/NCT02584387
NCT02584387UnknownNot Applicable

3D Video Virtual Reality Exposure Therapy (3D-VVRET) Study

University of Texas at Austin2 sites in 1 country40 target enrollmentStarted: September 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
40
Locations
2
Primary Endpoint
Fear of Spiders Questionnaire

Study Overview

Brief Summary

This study seeks to examine a Virtual Reality Exposure Therapy (VRET) using the 3D Video Virtual Reality (VR) technology for the fear of spiders.

Detailed Description

An estimated 10-11% of the US population experiences a specific phobia at some point in their lives (American Psychiatric Association, 1994; Magee et al., 1996). About 60-85% of those individuals with a specific phobia never seek treatment (Agras, Sylvester, & Oliveau, 1969; Boyd et al., 1990; Magee et al., 1996). Clinical psychologist can help improve the number of phobia sufferers to seek treatment. Advances in technology are helping clinicians create novel treatment strategies for different anxiety disorders. Virtual reality exposure therapy (VRET) may help these individuals confront their fears and treat their phobia.

While virtual reality exposure therapy has shown promise in research (Powers & Emmelkamp, 2008), studies have shown that many users complain that the computer generated virtual reality (VR) stimuli looks unrealistic, eccentric and too much like a video game (Kwon, Powell, & Chalmers, 2013). Virtual reality environments have been traditionally created by programmers using video game assets and computer generated imagery (CGI). While CGI can be used to make intricate virtual environments, unless there is a team of expert digital artists, the virtual stimulus may end up looking rudimentary and exhibit a number of graphical glitches which could prove distracting in therapy. Furthermore CGI often suffers from the uncanny valley effect: the tendency of CGI representations of people to be viewed as unsettling as the representations become more lifelike. In addition the many current CGI virtual reality packages are expensive and only available for limited number of fear domains. Recently however an exciting alternative to traditional computer generated virtual reality has emerged: ortho-stereoscopic 3D Video VR. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). The benefit of 3D VR as opposed to CGI VR is that it is photo realistic, does not suffer from a uncanny valley effect of CGI, and is able to capture nuances of real life fears that are hard to reproduce with CGI.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • • Between the ages of 18 and 65
  • At least one standard deviation above the SONA pool mean on Fear of Spiders Questionnaire or Acrophobia Questionnaire.

Exclusion Criteria

  • • Hearing or visually impaired where they cannot use the VRET gear
  • Currently (or in the last 3 months) receiving exposure-based treatment for acrophobia or arachnophobia

Arms & Interventions

Waitlist

No Intervention

Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.

3D VVRET

Experimental

Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)

1 30 minute 3D VRET treatment session for arachnophobia.

Intervention: 3D Video Virtual Reality Exposure Therapy (Behavioral)

Outcomes

Primary Outcomes

Fear of Spiders Questionnaire

Time Frame: Pre-treatment and 1 week follow-up

Secondary Outcomes

  • Distress Tolerance Scale (DTS)(Pre-treatment)
  • Disgust Emotion Scale(Pre-treatment)
  • Anxiety Sensitivity Index (ASI-3)(Pre-treatment)
  • State-Trait Anxiety Inventory(Pre-treatment)
  • Behavioral Approach Test(Pre-treatment and Post-treatment)
  • Acceptance and Action Questionnaire(Pre-treatment)
  • Disgust Propensity and Sensitivity Scale (DPSS-R)(Pre-treatment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mark B. Powers

Research Associate Professor

University of Texas at Austin

Study Sites (2)

Loading locations...

Similar Trials